Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

We depend on our government to enforce regulations that protect our health. And for nearly half of a century, Americans have relied on dietary guidance from the federal government to stay healthy.

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

Live Updates Get The Best AMD Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on AMD, ...

A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...

Bestselling author and speaker Maja Kazazic releases Scale Up Blueprint™, a practical 7-block framework for resilient growth ...

Moderna ( MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back against immunizations.

Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential.

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.